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Abstract: Multiple sclerosis (MS) is the most common autoimmune illness of the central 
nervous system. For many years the inflammatory manifestations of MS were treated using only 
corticosteroids. Since the 1990s the results of several clinical trials with immunomodulatory 
agents have changed the therapeutic approach to this disease. Interferon beta (IFNβ)-1b 
represents the pioneer of those therapies. There is growing evidence from clinical trials on 
relapsing-remitting MS and clinically isolated syndromes suggestive of MS that IFNβ-1b reduces 
the frequency and severity of relapses and the development of new and active brain lesions 
as assessed by magnetic resonance imaging. Long-term data suggest a persistent efficacy of 
IFNβ-1b on disease activity and a positive effect in slowing disability worsening. Furthermore 
a reduction of relapse rate and a slight positive effect on the progression were demonstrated 
when IFNβ-1b was administered to still-active secondary progressive MS. IFNβ-1b therapy 
is well tolerated and relatively free of long-term side effects. In spite of the emergence of new 
agents for the treatment of MS, IFNβ-1b still remains a first-line therapy with a fundamental 
role in all stages of the disease.
Keywords: interferon beta-1b, relapsing-remitting multiple sclerosis, clinically isolated 
syndromes, efficacy, safety, neutralizing antibodies
Introduction
Interferon beta (IFNβ)-1b was the first immunomodulatory therapy approved for the 
treatment of relapsing-remitting (RR) multiple sclerosis (MS)1–2 and currently is the 
only IFNβ licensed for use in secondary progressive (SP) MS.3 Moreover, recent 
studies4–5 have defined IFNβ-1b efficacy in treating patients with clinically isolated 
syndrome (CIS).6
In this review we focus on biologic activity, clinical and magnetic resonance 
imaging (MRI) evidence of efficacy, and safety of IFNβ-1b in RRMS and patients 
with CIS.
Pharmacokinetics and pharmacodynamics  
of IFNβ-1b
Human IFNβ-1b (Betaferon®/Betaseron®; Bayer HealthCare) is a lyophilized protein 
produced by DNA recombinant technology by Esecheria coli. As bacteria lack the 
ability to glycosylate proteins, the recombinant protein was not glycosylated. The 
cysteine residue at position 17 was replaced with a serine residue to ensure the stability 
of the molecule and the N-terminal methionine residue was deleted.7 It is combined 
with mannitol and human albumin to reach a neutral pH of 7.2.Biologics: Targets & Therapy 2009:3 370
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Assessment of serum IFNβ concentrations is technically 
difficult and, thus, the pharmacokinetic characteristics of 
IFNβ-1b are not well described. Lower serum concentrations 
of IFNβ-1b were detected after subcutaneous (SC) compared 
with intravenous administration, with a relative bioavail-
ability of 51%.8 The liver is probably the predominant site 
of metabolism.9
The mechanisms of action of IFNβ are not yet finally 
understood, but there is agreement that the major effects are:
•  inhibition of T lymphocyte proliferation and decrease of 
IFN-γ production;10
•  inhibition of major histocompatibility complex class II 
(MHC II) expression, with reduced antigen presentation 
within central nervous system (CNS);11
•  inhibition of matrix metalloproteinase (MMP) production 
and cell-associated adhesion molecule expression;12–14
•  induction of anti-inflammatory and inhibition of 
pro-inflammatory cytokines;15–17
•  induction of CD8 regulatory cell function and inhibition 
of monocyte activation.18
Pilot dose-finding trials of IFNβ-1b
A pilot study19 demonstrated that a dose of 250 µg of SC 
IFNβ-1b increased CD8 cell-mediated suppressor activity in 
MS patients to levels approaching those in patients without 
MS. Lower doses showed a lesser effect on CD8 suppressor 
cell function, suggesting an adequate dosing is important 
for IFNβ-1b treatment. In a pilot dose-finding trial of SC 
IFNβ-1b,20 5 groups of RRMS, each including 6 patients, 
were treated with 25, 125, 250 or 500 µg of IFNβ-1b or 
placebo, respectively, 3 times weekly. The dose-finding 
results (after 24 weeks) showed a dose-related reduction of 
relapse frequency. However, patients receiving the highest 
dose of IFNβ-1b experienced side effects that led to a dose 
reduction or dropout within a short time-frame. Four of 
these patients subsequently received the 250 µg dose. The 
10 patients receiving the 250 µg dose of IFNβ-1b, at the end 
of the study, had a reduced attack frequency compared to the 
6 patients receiving placebo. Based on these results, a dose 
of 250 µg of IFNβ-1b every other day (EOD) was selected 
for further investigation.
Efficacy of IFNβ-1b in RRMS
In 1993 a double-blind, placebo-controlled phase III trial1 
led to approval of IFNβ-1b as the first therapeutic agent for 
RRMS. It included 372 patients with RRMS who had scores on 
the Expanded Disability Status Scale (EDSS) 5.5 and who 
had experienced at least two attacks in the previous 2 years. 
Patients were randomized to receive placebo, low dosage 
(50 µg) or high dosage (250 µg) of SC IFNβ-1b EOD for 
2 years. Exacerbation rates (primary endpoint of the study) 
were significantly lower in both treatment groups compared 
with the placebo group (high dosage vs placebo P = 0.0001; 
low dosage vs placebo P = 0.01) and in high dosage vs low 
dosage group (P = 0.0086), suggesting a dosage effect. 
The MRI results2 supported the clinical results showing 
a significant reduction of T2 active scans (high dosage 
vs placebo P = 0.0089; low dosage vs placebo P = 0.04), 
appearance of new T2 lesions (high dosage vs placebo 
P = 0.0026; low dosage vs placebo P = 0.03) and MRI burden 
of disease (high dosage vs placebo P  0.001; low dosage 
vs placebo P = 0.04) in the treatment groups as compared 
with placebo group. An extension study, lasting up to 5 years, 
showed that IFNβ-1b at dose of SC 250 µg EOD continued to 
have a persistent effect on exacerbation rate reduction (-33%) 
and MRI burden of disease, and was relatively free of long-
term side effects.21 Moreover a post-hoc analysis showed that 
the beneficial effect of IFNβ-1b on relapse frequency had 
rapid onset, an effect being observed as early as the second 
month of treatment.22 The increase in MRI lesion burden in 
the placebo arm was approximately 5-fold higher than that 
seen in the higher dose IFNβ-1b group, and even the lower 
dose reduced MRI lesion burden substantially.
A more recent study23 on 30 RRMS patients, followed 
monthly for a 6-month baseline period and then for a period 
up to 36 months from the start of treatment with IFNβ-1b 
(SC 250 µg EOD), demonstrated a significant effect of the 
drug in slowing the progression of cerebral atrophy during 
years 2 and 3.
To evaluate long-term safety and efficacy of IFNβ-1b 
in RRMS patients, a multicenter, open-label, observational 
study was conducted up to 16 years of follow-up using cross-
sectional data collection from patients having participated in 
the original pivotal trial.24 Survival, disease status, relapse 
rate, EDSS score, adverse events, MRI data were collected. 
The results were analysed by stratification according to the 
original assignment of the pivotal trial (placebo, 50 µg, 
250 µg of IFNβ-1b) and according to the duration of treat-
ment exposition during 16 years of follow-up (20% of 
exposition; 20% to 80%; 80%). Eighty-eight percent of the 
patients from the original trial participated in the long-term 
follow-up. High adherence to the treatment was evidenced 
by the median treatment duration of the whole cohort (almost 
10 years). The final results of this longer follow-up study 
suggested that early and continuous long-term treatment 
with IFNβ-1b was favorable for the patients, since relapse Biologics: Targets & Therapy 2009:3 371
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frequency reduction was similar to the pivotal study (40%), 
and progression of disability, evaluated at the EDSS score 
of 6 (unable to walk without assistance), was even slower 
in patients exposed for a longer period compared to other 
groups with a shorter period of treatment.
These reported results24 were confirmed by a more 
recently published long-term observational study25 showing 
that IFN-β treated patients have a significant reduction in 
the incidence of secondary progression, EDSS 4.0 and 6.0, 
compared with untreated patients, during a follow-up lasting 
up to 7 years.
Efficacy of IFNβ-1b in patients  
with CIS
MRI and histological findings demonstrate that irrevers-
ible axonal damage begins early in the course of MS.26,27 
Furthermore, neuropathological findings suggest the potential 
for immunomodulatory treatment of MS to have a greater 
effect early in the disease course.28–29 Three multicenter, 
placebo-controlled studies,30–34 have shown that IFNβ treat-
ment delays conversion to clinically definite MS (CDMS)32 
when administered to patients with CIS (Table 1). However the 
Betaferon/Betaseron in Newly Emerging Multiple Sclerosis 
For Initial Treatment (BENEFIT) study4 was also designed 
to assess if early initiation of treatment with IFNβ-1b is 
more efficacious than a delayed treatment for preventing the 
development of long-term confirmed disability.
Between February 2002 and June 2003, patients with 
CIS from 18 European countries, Israel, and Canada were 
randomized in 98 centers. The inclusion criteria were: age 
between 18 and 45 years, a first clinical neurological event 
suggestive of MS, at least two clinically silent lesions on their 
T2-weighted brain MRI scan (at least one of which being 
ovoid, periventricular, or infratentorial), and EDSS score 
of 0 to 5. Study treatment had to be started within 60 days 
after onset of the first clinical event. Patients were centrally 
randomized (in a 5:3 ratio) to IFNβ-1b 250 µg (8 MIU) or 
placebo SC EOD and scheduled to receive double-blinded 
injections for up to 2 years or until CDMS was reached. This 
first phase ended in 2005 and assessed the efficacy, safety and 
tolerability of IFNβ-1b 250 µg. After 2 years, 45% of placebo 
patients had converted to CDMS (primary outcome measure) 
and 85% fulfilled the McDonald criteria (co-primary outcome 
measure). Overall IFNβ-1b delayed the time to diagnosis of 
CDMS (P  0.0001) and McDonald MS (P  0.00001). The 
risk for CDMS in the IFNβ-1b group was reduced by 50% 
and for Mc Donald MS by 46%. Based on Kaplan-Meier 
estimates, the probability of the development of CDMS over 
Table 1 Placebo-controlled studies of iFNβ treatment in patients with clinically isolated syndromes (CIS): comparison of beneficial effects 
on probability of conversion to clinically definite multiple sclerosis (CDMS) and magnetic resonance imaging measures
Drug 
 
Study 
 
Study design 
 
Follow-up 
years 
No. of  
patients 
Probability 
of conversion 
to CDMS (%)e
No. of new or  
enlarging lesions 
No. Gd+ lesions 
 
iFNβ-1a 30 µg iM 
Ow (Avonex®)
CHAMPSa (2000) treated vs 
placebo
3 years 383 35 vs 50%  
P = 0.002
2.1 ± 3.2 (M ± SD) vs 
5.0 ± 7.7 (M ± SD)  
P  0.001
0.4 ± 1.5 (M ± SD) vs 
1.4 + 3.6 (M ± SD) 
P  0.001
CHAMPiONSb (2006) early vs 
delayed 
treatment
5 years 203 36 vs 49%  
P = 0.03
3.5 (0.5–8.5) vs  
6.0 (2.0–13.0)  
P = 0.05
1 lesions  
29% vs 30%  
P = n.s.
iFNβ-1a 22 µg SC 
Ow (rebif® 22)
eTOMSc (2001) treated vs 
placebo
2 years 309 34 vs 45%  
P = 0.047
2.0 (0.5–4.5) 
(median) vs  
3.0 (1.5–6.25) 
(median) P  0.001
0.5 (0–1) (median) vs 
0 (0–1) (median)  
P = n.s.
i iFNβ-1b 
250 µg SC eOD 
(Betaferon®)
BeNeFiTd (2006) treated vs 
placebo
2 years 468 25 vs 44%  
P  0.0001
2.9 ± 4.9 (M ± SD) vs 
4.4 ± 5.7 (M ± SD)  
P  0.0001
1.9 ± 5.2 (M ± SD) vs 
4.3 ± 7.1 (M ± SD)  
P  0.0001
BeNeFiTd (2007) early vs 
delayed 
treatment
3 years 418 37 vs 51%  
P = 0.001
18 (7.0–39.0) 
(Median) vs 17  
(8.0–37) (median) n.s.
0 (0.0–1.0) (median) 
vs 0 (0.0–1.0) 
(median) n.s.
aControlled high risk subjects Avonex® Multiple Sclerosis Prevention Study.
bControlled high risk subjects Avonex® Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance.
cearly Treatment of Multiple Sclerosis Study.
dBetaferon®/Betaseron® in Newly emerging Multiple Sclerosis for initial Treatment.
eBased on Kaplan-Meier life tables.
Abbreviations: eOw, every other week; iM, intramuscular; SC, subcutaneous; Ow, once weekly.Biologics: Targets & Therapy 2009:3 372
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2 years was reduced by treatment from 45% in the placebo 
group to 28% in the IFNβ-1b group corresponding to an abso-
lute risk reduction by 17%. IFNβ-1b prolonged the time to 
CDMS by 363 days (255 days in the placebo group, 618 days 
in the IFNβ-1b group). The patient number needed to be 
treated (NNT) in order to prevent one case of CDMS within 
the study period of 2 years was estimated to be 5.9. Within the 
first 6 months, the probability to reach MS diagnosis accord-
ing to the McDonald criteria was 51% for placebo and 28% 
for IFNβ-1b-treated patients. Within 2 years this probability 
was reduced by treatment from 85% in the placebo group 
to 69% in the IFNβ-1b group, corresponding to an absolute 
risk reduction of 16%. There was also a significant treat-
ment effect of IFNβ-1b on time to CDMS in all subgroups 
defined by different baseline characteristics (monofocal or 
multifocal manifestation, number of T2 lesions 9 or 9 
and absence or presence of at least one gadolinium positive 
[Gd+] lesion in the screening MRI). The treatment effect was 
more pronounced in patient subgroups with less inflamma-
tory disease activity as documented by Gd enhancement or 
T2 lesions count and less dissemination in space at the time 
of the first event. The MRI results33 from patients complet-
ing 2 years of follow-up demonstrated that IFNβ-1b had 
a robust effect on MRI measures: the cumulative number 
of new T2 lesions and new Gd+ lesions was 60% lower in 
patients receiving IFNβ-1b vs placebo. A robust treatment 
effect was found throughout all subgroups defined by clinical 
and MRI measures of disease activity or dissemination in 
space at onset. The subgroups analysis reveals a consistently 
stronger treatment effect in patients with monofocal clinical 
presentation, fewer T2 lesions, or not contrast enhancement at 
baseline, confirming that treatment was particularly beneficial 
in patients with less active or disseminated disease.
Patients who completed the placebo-controlled phase 
were eligible to participate to a single-arm (IFNβ-1b) 
follow-up phase lasting at least 5 years from the period of 
randomization.5 This was prospectively designed to explore 
the long-term impact of early vs delayed treatment on pro-
gression of neurological disability and on brain MRI mea-
sures, including outcomes of neurodegeneration such as brain 
atrophy. Primary outcomes were time to diagnosis of CDMS 
and time to confirmed EDSS progression. Of the 468 patients 
originally randomized, 418 (89%) entered the follow-up 
phase; 392 (84%) completed 3 years post-randomization 
follow-up. After 3 years 99 (37%) patients in the early group 
developed CDMS compared with 85 (51%) patients in the 
delayed treatment group.6 Early treatment reduced the risk 
of CDMS by 41% compared with delayed treatment. Over 
3 years, 42 (16%) patients in the early group and 40 (24%) 
in the delayed group had confirmed EDSS progression; early 
treatment reduced the risk for progression of disability by 
40% compared with delayed treatment.
Polman at al34 evaluated the impact of the demographic, 
clinical and MRI parameters on the ‘natural’ risk of MS in 
placebo-treated patients, and the IFNβ-1b treatment effect 
in subgroups of the study population. Four hundred and 
sixty-eight out of 483 patients from the BENEFIT (IFNβ-1b: 
n = 292; placebo: n = 176) were grouped according to demo-
graphic, clinical, cerebrospinal fluid (CSF), and MRI findings 
at disease onset. The ‘natural’ risk of CDMS over 2 years 
was estimated by Kaplan-Meier statistics in placebo-treated 
patients; the IFNβ-1b treatment effect was analysed by 
Cox proportional hazards regression. In the placebo-treated 
group a higher risk to develop CDMS was found in younger 
(30 vs 30 years: 60% vs 33%), CSF-positive patients 
(49 % vs 36%), in those who had received steroid treatment 
(48% vs 38%) and had 9 T2 (48% vs 39%) or 1 Gd+ 
T1 (52% vs 41%) MRI lesions. The CDMS risk was higher 
(75%) in placebo-treated patients with monofocal disease 
onset displaying higher MRI disease activity (1 Gd+ lesion) 
and dissemination (9 T2– lesions).
Treatment effects on time to CDMS conversion were 
significant in all subgroups, with a greater impact on patients 
with less disease dissemination/activity at onset (monofocal 
vs multifocal: 55% vs 37%; 9 vs 9 MRI T2– lesions: 
60% vs 43%; absence vs presence of MRI Gd+ lesions: 57% 
vs 38%). Moreover monofocal patients had further greater 
treatment effects if they had  9 T2– lesions or presence of 
Gd+ lesions, or both.
Efficacy of IFNβ-1b in SPMS
Two large placebo-controlled studies of IFNβ-1b in 
SPMS have been conducted: the European study and the 
North-American study.3,35 In both studies, IFNβ-1b 250 µg 
recipients had fewer relapses and less MRI-assessed disease 
activity than placebo recipients. Only the European trial3 
provided evidence that the treatment delays the progression 
of the disease. The conflicting result on the primary endpoint 
might be explained by differences in the inclusion criteria 
and baseline characteristics of the study populations. In the 
European SPMS trial, the patients appeared to be younger, 
with a shorter duration of disease, faster disease progression 
and disease characteristics thought to reflect the inflammatory 
component of the illness, such as higher relapse rates and a 
greater number of contrast enhancing lesions. These results 
were supported by a post-hoc analysis of the European SP Biologics: Targets & Therapy 2009:3 373
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MS trial36 in which patients with higher pre-study disease 
activity (2 relapses, EDSS progression 1 point over 
the 2 years before study) seemed to have a more favorable 
treatment effect.
Head-to-head comparative  
studies of IFNβ-1b
Low dose IFNβ-1a intramuscular (IM) was compared with 
high dose IFNB-1b SC in 188 patients of the Independent 
Comparison of Interferon (INCOMIN) study.37 After 2 years 
the percentage of patients free from relapses and from new 
T2 or Gd+ lesions was higher in IFNβ-1b than in IFNβ-1a 
group. Patients in high-dose IFNβ-1b had a lower risk for 
confirmed disability progression (EDSS increase of at least 
one point sustained for at least 6 months and confirmed at the 
end of follow-up) than those in low-dose IFNβ-1a.
The Betaferon®/Betaseron® Efficacy Yielding Outcomes 
of a New Dose (BEYOND) study38 investigated the effect of 
two high doses of IFNβ-1b regimens (500 µg and 250 µg SC 
EOD) or glatiramer acetate (GA) in RRMS treatment-naïve 
patients (N = 2244).
Patients with age between 18 and 55 and EDSS in 0 to 5 
range were enrolled. There were no significant differences 
between the two IFNβ-1b regimen groups for the primary 
and secondary clinical (relapse-related measures, progression 
as assessed by EDSS score) and MRI (new T2 lesions, and 
volume of T2 and Gd+ lesions) outcomes. The comparison 
between IFNβ-1b arms and GA arm showed similar treatment 
effects on clinical endpoints,38–39 but a significant superior 
effect of both IFNβ-1b arms on the cumulative number of 
T2 lesions up to the last scan and on the relative increase in 
T2 lesion volume.40
A Danish head-to-head, controlled, open-label, random-
ized study aimed to compare the effects of IFNβ-1b 250 µg 
EOD with IFNβ-1a 22 µg once weekly (OW) in RRMS 
did not prove significant differences on clinical and MRI 
measures during a period of a follow-up of 2 years.41
Clinical relevance of neutralizing 
antibodies against IFNβ
During IFNβ therapy a significant percentage of patients 
develop neutralizing antibodies to IFNβ (NAbs).
In the pivotal phase III trial of IFNβ-1b,1 35% of 
treated patients developed NAbs to IFNβ-1b. In this study 
a sample was considered positive if the NAb titer was at 
least 20 NU/mL based on a viral cytopathic effect reduction 
assay (CPE). NAb positive (NAb+) patients were the ones 
with two consecutive positive samples, 3 months apart.
The results from an extensive study aimed to assess the 
therapeutic impact of Nabs42 suggested a lesser efficacy 
of IFNβ-1b in NAb+ patients with respect to relapse rate 
reduction, whereas the disease progression in NAb+ patients 
appeared less marked than in NAb negative (NAb–) patients. 
Similar results were reported by a number of other short-term 
trials,43–46 demonstrating that patients who develop NAbs to 
both IFNβ-1b and 1a were associated with higher relapse 
rates and lesion activity on MRI, but without relevant effect 
on disability progression.
A longer-term follow-up47 of  two cohorts from the original 
pivotal IFNβ-1b trial provided further data on the develop-
ment of NAbs showing their transient nature. Moreover this 
study demonstrated that 91% of NAb+ patients reverted to 
NAb– status after 8 years of treatment. A longitudinal study48 
confirmed that high titres of NAbs suppress the relapse-
reducing efficacy of IFNβ. However since a gradual reduction 
in titres appeared and NAbs frequently became undetectable 
with the continuation of the therapy, extending the medica-
tion resulted in full return of efficacy for the 20% of patients 
for whom the appearance of NAbs was clinically significant. 
Sorensen et al 49 evaluated the clinical relevance of NAbs in 
541 RRMS who started treatment with IFNβ between 1996 and 
1999 in Denmark. The results showed that relapse rates were 
significantly (P  0.03) higher during NAb+ periods (0.64 
to 0.70) than they were during NAb– periods (0.43 to 0.46). 
Time to first relapse was significantly increased by 244 days 
in patients who were NAB– at 12 months (log rank test 6.83, 
P = 0.009). During a follow-up period of 60 months, the 
presence of NAbs did not affect significantly the disability 
progression as measured by time to confirmed progression of 
1 point on EDSS, sustained for at least 6 months.
The INCOMIN study37 showed a greater frequency of 
NAb+ patients in the group treated with high-dose IFNβ-1b 
SC in comparison to those treated with low-dose IFNβ-1a 
IM, in spite of better clinical and MRI outcome.
In a more recent prospective, multicenter, observational 
study by the same authors,50 MRI activity and NAb positivity 
(assessed by M×A protein assay) in the first 6 months of 
IFNβ treatment resulted predictors of long term clinical 
response (occurrence of one or more relapses or confirmed 
disease progression), particularly when combined. Patients 
with negative predictors showed less than 10% risk of 
developing clinical activity, while patients with positive 
predictors showed a 50% risk of further clinical activity. 
Similar conclusions were reached by another group in 
patients treated with IFNβ-1a or IFNβ-1b, measuring the 
IFNβ bioavailability marker mRNA M×A.51Biologics: Targets & Therapy 2009:3 374
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In CIS patients included in the BENEFIT study the 
incidence of positive NAb titers ranged from 16.5% to 25.2% 
of the treated patients.4 Neutralizing activity was detected 
at least once in 75 out of 251 (29.9%) IFNβ-1b patients 
who provided samples during the treatment phase; of these, 
17 (22.7%) converted to negative status later in the study. 
No significant effect of NAb status on time to CDMS in 
IFNβ-1b treated patients was found; in this analysis there 
was a trend toward a lower risk of progressing to CDMS in 
patients with at least one positive NAb titer. When analyses 
were performed at the end of the study (at least 180, 270 
or 360 days after start of treatment) no differences were 
observed between NAb+ and Nab– patients.
The clinical impact of NAbs on treatment efficacy in 
6698 MS patients receiving IFNβ-1b was investigated by 
Goodin et al52 suggesting that NAbs are not responsible for 
poor clinical responses and NAb status is of little clinical 
value.
In conclusion the results derived from existing studies 
are conflicting and have to be interpreted with caution. 
The differences might be due to the different duration of 
follow-up, assays and definitions of NAb positivity used. 
The impact of NAbs seems to be more frequently evident 
on proper inflammatory clinical events of MS (relapse rate) 
but the influence of NAbs on the progression of the disease 
remains uncertain. Therefore the decisions to discontinue 
IFNβ therapy are still based mainly on the patient’s clinical 
response to the treatment.
IFNβ-1b and adverse events
The administration of IFNβ is associated with the risk 
of a variety of adverse effects53,54 The most common, 
compared with placebo, are flu-like symptoms and, in 
SC-treated patients, injection-site reactions.53 In the pivotal 
IFNβ-1b trial,1 flu-like symptoms in the high-dose group 
were initially observed in 52% of patients. However, by 
the end of the first year, these had decreased to 8%, only 
3% to 8% of patients experiencing symptoms throughout 
the study. Injection-site reactions in the same pivotal trial 
were initially reported by 80% of those receiving 250 µg 
IFNβ-1b, a figure that declined to between 44% and 50% 
at years 4 and 5.
During the first year of the BEYOND study,55 flu-like 
symptoms were reported significantly more frequently in 
the IFNβ-1b 250 µg group compared to the GA group. 
Although initially high, the frequency of flu-like symptoms 
in IFNβ treated group declined very quickly over time. 
For injection-site reactions, pain and pruritus were 
significantly more frequent in the GA treatment group than in 
the IFNβ-1b 250 µg group, but in the same way, the incidence 
of this reactions decreased over the study. The incidence of 
other adverse events such as fatigue, depression, arthralgia 
and paresthesia was comparable between treatments groups. 
The evaluation of laboratory safety as elevations in liver 
enzymes abnormalities, in blood lipids and markers of 
thyroid function, as well as leukocytopenia were more 
frequently detected in patients treated with IFNβ-1b than 
in those treated with GA. Adherence to treatment was also 
assessed demonstrating that the adherence to treatment was 
high in all three treatment groups.56,57 The proportion of 
patients completing the anticipated treatment period ranged 
from 73% in the IFNβ-1b 500 µg group through 78% in GA 
group to 82% in the IFNβ-1b 250 µg group. No significant 
differences in discontinuation rates were observed among 
the groups.
The management of IFNβ-related side effects is of great 
importance to improve the patients’s treatment adherence. 
General precautions to reduce or avoid this side effect 
include the correct preparation of the injection solution 
and a proper injection technique. In all studies frequency 
and severity of adverse effects depend on the duration of 
treatment and they are at a maximum during the first weeks 
of treatment.
Conclusions
Results from rationally planned and statistically convincing 
studies in RRMS and CIS patients demonstrated that IFNβ-1b 
treatment has very favorable efficacy on clinical and MRI 
measures of disease activity and progression since very early 
stages of disease.
Early and continuous treatment with IFNβ-1b maintains 
persistent effectiveness and safety in the long term. 
A reduction in attack rate and a slight positive effect 
on the progression of disability were also demonstrated 
when IFNβ-1b was administered to patients in SP phase. 
Therefore IFNβ-1b still represents a key therapeutic 
option for MS patients, playing a fundamental role in all 
stages of the disease. No definitive relationship between 
development of NAbs and response to treatment has been 
demonstrated.
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